Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.39 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.33 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.33 |
| ▸ | ITGAL | P20701 | 1/20 | 0.33 |
| ▸ | OXTR | P30559 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4728144 | 0.76 | MAOA (0.42) | MAOBMAOATSHRABCG2CES1 | |
| SCHEMBL28898666 | 0.68 | ITGB2 (0.44) | MAOBMAOAABCG2ITGB2ICAM1 | |
| SCHEMBL30360775 | 0.67 | MAOA (0.70) | MAOBMAOATSHRABCG2CES1 | |
| SCHEMBL971330 | 0.67 | MAOA (0.70) | MAOBMAOATSHRABCG2CES1 | |
| SCHEMBL5079833 | 0.67 | MAOA (0.34) | MAOBMAOA | |
| Hydrochloric Acid SCHEMBL8209470 | 0.66 | MAOA (0.33) | MAOBMAOA | |
| Hydrochloric Acid SCHEMBL8205757 | 0.66 | MAOA (0.33) | MAOBMAOA | |
| SCHEMBL7142311 | 0.65 | TSHR (0.42) | MAOBMAOATSHRCES1CYP2A6 | |
| SCHEMBL3649668 | 0.65 | MAOB (0.38) | MAOBMAOATSHRCES1CYP2A6 | |
| Bicarbonate SCHEMBL8663458 | 0.64 | SRD5A1 (0.40) | MAOBMAOACES1CYP2A6GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645776-B2 | (R)-1-{2-[3-(4-Methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone; carnitine-dependent palmitoyltransferases (CPTs); reduce liver beta -oxidation, consequently inhibit gluconeogenesis and therefore counteract hyperglycemia | HOFFMANN-LA ROCHE INC. (US) | 2010-01-12 | — | — | US | claimed |
| EP-1959951-B1 | HETEROARYL SUBSTITUTED PIPERIDINE DERIVATIVES AS L-CPT1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-12-23 | — | — | EP | claimed |
| EP-1959951-A1 | HETEROARYL SUBSTITUTED PIPERIDINE DERIVATIVES AS L-CPT1 INHIBITORS | F. Hoffmann-la Roche AG (CH) | 2008-08-27 | — | — | EP | claimed |
| WO-2007063012-A1 | HETEROARYL SUBSTITUTED PIPERIDINE DERIVATIVES AS L-CPT1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-07 | — | — | WO | claimed |
| US-20070129544-A1 | (R)-1-{2-[3-(4-Methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone; carnitine-dependent palmitoyltransferases (CPTs); reduce liver beta -oxidation, consequently inhibit gluconeogenesis and therefore counteract hyperglycemia | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-07 | — | — | US | claimed |
| US-7645776-B2 | (R)-1-{2-[3-(4-Methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone; carnitine-dependent palmitoyltransferases (CPTs); reduce liver beta -oxidation, consequently inhibit gluconeogenesis and therefore counteract hyperglycemia | HOFFMANN-LA ROCHE INC. (US) | 2010-01-12 | — | — | US | disclosed |
| EP-1959951-B1 | HETEROARYL SUBSTITUTED PIPERIDINE DERIVATIVES AS L-CPT1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-12-23 | — | — | EP | disclosed |
| EP-1959951-A1 | HETEROARYL SUBSTITUTED PIPERIDINE DERIVATIVES AS L-CPT1 INHIBITORS | F. Hoffmann-la Roche AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| EP-1853625-A2 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR | GENENTECH, INC. (US) | 2007-11-14 | — | — | EP | disclosed |
| WO-2007063012-A1 | HETEROARYL SUBSTITUTED PIPERIDINE DERIVATIVES AS L-CPT1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-07 | — | — | WO | disclosed |
| US-20070129544-A1 | (R)-1-{2-[3-(4-Methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone; carnitine-dependent palmitoyltransferases (CPTs); reduce liver beta -oxidation, consequently inhibit gluconeogenesis and therefore counteract hyperglycemia | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-07 | — | — | US | disclosed |
| WO-2006081272-A2 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR | GENENTECH, INC. (US) | 2006-08-03 | — | — | WO | disclosed |
| EP-1490385-A2 | JAGGED 2 INHIBITORS FOR INDUCING APOPTOSIS | ISIS PHARMACEUTICALS, INC. (US) | 2004-12-29 | — | — | EP | disclosed |
| US-20030232440-A1 | Antisense modulation of STAT1 expression | ISIS PHARMACEUTICALS INC. | 2003-12-18 | — | — | US | disclosed |
| WO-2003102242-A1 | NOTCH 1 INHIBITORS FOR INDUCING APOPOTOSIS | ISIS PHARMACEUTICALS, INC. (US) | 2003-12-11 | — | — | WO | disclosed |
| WO-2003102008-A1 | ANTISENSE MODULATION OF TRANSCRIPTION FACTOR DP-1 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2003-12-11 | — | — | WO | disclosed |
| WO-2003077848-A2 | JAGGED 2 INHIBITORS FOR INDUCING APOPTOSIS | ISIS PHARMACEUTICALS, INC. (US) | 2003-09-25 | — | — | WO | disclosed |
| WO-2003057142-A2 | ANTISENSE MODULATION OF MACROPHAGE INFLAMMATORY PROTEIN 3-ALPHA EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2003-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129544-A1 | (R)-1-{2-[3-(4-Methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone; carnitine-dependent palmitoyltransferases (CPTs); reduce liver beta -oxidation, consequently inhibit gluconeogenesis and therefore counteract hyperglycemia | CPT1A, CPT1B, CPT2 | MAOB 1130/4885MAOA 1684/4885TSHR 2243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.